3Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation[J]. Clin pharmacol Ther, 1993,55;205.
4Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration - time curve[J]. Translantation, 1999,68; 55.
5Johnston A, David OJ, Cooney GF. Pharmacokinetic validation of Neoral absorption profiling[J]. Transplant Proc, 2000, 32(3): 53.
6Bjom N, Edward C, Gary L, et al. Clinical validation studies of Neoral C2 monitoring: a review[J]. Transplantation, 2002,73(9): 3.
7Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo [J ]. Transplantation, 1999, 68:1356.
8Lind Holm A.Therapeutic monitoring of cyclosporine an update[J].Eur J Clin Pharmacol,1991,14:114.
7Einollahi B,Rostami Z,Kalantar E. Is the lower cyclosporine concentration at 2 hours after dosing safe in kidney transplant recipients[J].Transplantation Proceedings,2011,(02):488-490.
8Mino Y,Naito T,Otsuka A. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase[J].Journal of Clinical Pharmacy and therapeutics,2011,(02):217-224.
9Yamaoka M,Kawamura R,Shioda Y. Analysis of the plasma concentration of tacrolimus:a useful method for distinguishing falsely elevated tacrolimus concentrations reported by the ACMIA[J].Japanese Journal of Clinical Pathology,2010,(12):1188-1192.
10Stracke S,Shipkova M,Mayer J. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation[J].Clinical Transplantation,2012,(01):57-66.
